BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 21039835)

  • 1. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
    Carr BI; Carroll S; Muszbek N; Gondek K
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1739-46. PubMed ID: 21039835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada.
    Muszbek N; Shah S; Carroll S; McDonald H; Dale P; Maroun J; Knox J
    Curr Med Res Opin; 2008 Dec; 24(12):3559-69. PubMed ID: 19032137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib for the treatment of advanced hepatocellular carcinoma.
    Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
    Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
    Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
    Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
    Zhang P; Yang Y; Wen F; He X; Tang R; Du Z; Zhou J; Zhang J; Li Q
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):853-9. PubMed ID: 25919775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
    Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
    Value Health; 2010; 13(1):55-60. PubMed ID: 19804431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States.
    Sieg M; Hartmann M; Settmacher U; Arefian H
    BMC Gastroenterol; 2020 Apr; 20(1):120. PubMed ID: 32316925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
    Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
    Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
    Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
    J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
    Vitale A; Volk ML; Pastorelli D; Lonardi S; Farinati F; Burra P; Angeli P; Cillo U
    Hepatology; 2010 Jan; 51(1):165-73. PubMed ID: 19877181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
    Shlomai A; Leshno M; Goldstein DA
    PLoS One; 2018; 13(11):e0207132. PubMed ID: 30408106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life and sorafenib.
    Spinzi G; Terreni N
    Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Leung HW; Liu CF; Chan AL
    Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Parikh ND; Singal AG; Hutton DW
    Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
    Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From a cancer drug fund to value based pricing of drugs.
    Duerden M
    BMJ; 2010 Aug; 341():c4388. PubMed ID: 20705656
    [No Abstract]   [Full Text] [Related]  

  • 20. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
    Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.